Relationship Between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies

Overview

Journal J Thorac Oncol

Publisher Elsevier

Specialties Oncology
Pulmonary Medicine

Date 2016 Aug 7

PMID 27496650

Citations 38

Authors

Takehito Shukuya

Keita Mori

Joseph M Amann

Erin M Bertino

Gregory A Otterson

Peter G Shields

Satoshi Morita

David P Carbone

Affiliations

Soon will be listed here.

Abstract

Introduction: Alternative predictive end points for overall survival (OS), such as tumor response and progression-free survival (PFS), are useful in the early detection of drug efficacy; however, they have not been fully investigated in patients with advanced NSCLC treated with anti-programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies.

Methods: In a systematic review of the reported prospective clinical trials, data for response rate, median PFS, and median OS were extracted from 12 arms in 10 reported clinical trials using anti-PD-1/PD-L1 antibody, and their correlation was investigated. In a retrospective analysis at our institution, OS was compared according to tumor response on 5- to 9-week computed tomography scans and status of being progression-free at 8, 16, and 24 weeks by landmark analysis in 71 patients with advanced NSCLC treated with anti-PD-1/PD-L1 antibodies between 2013 and 2015.

Results: In a systematic review, moderate correlations between median OS and median PFS (p = 0.120, r = 0.473) and between median OS and response rate (p = 0.141, r = 0.452) were identified using the Spearman correlation coefficient, although these correlations were not statistically significant. In a retrospective analysis of patients treated at our institution, disease control (partial response [PR]/stable disease versus progressive disease/not evaluable), and progression-free status at 8, 16, and 24 weeks significantly predicted OS (Cox proportional hazards model, PR/stable disease versus progressive disease/not evaluable, p = 0.0104, HR = 3.041; 8-week progression-free yes versus no, p = 0.0183, HR = 2.684; 16-week progression-free yes versus no, p = 0.0036, HR = 4.009; and 24-week progression-free yes versus no, p = 0.0002, HR = 12.726).

Conclusions: Both disease control (PR plus stable disease status) and landmark progression-free survival were correlated with OS, with the longer interval landmark PFS being the best predictor of survival in patients with NSCLC treated with anti-PD-1/PD-L1 antibodies.

Citing Articles

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study.

Krebs M, Forster M, Majem M, Peguero J, Iams W, Clay T JTO Clin Res Rep. 2024; 5(11):100725.

PMID: 39403626 PMC: 11472608. DOI: 10.1016/j.jtocrr.2024.100725.

Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study.

Chen C, Luo X, Tang W, Geng H, Martinez-Perez J, Price T J Gastrointest Oncol. 2024; 15(4):1497-1507.

PMID: 39279938 PMC: 11399868. DOI: 10.21037/jgo-24-468.

Machine learning and bioinformatics analysis of diagnostic biomarkers associated with the occurrence and development of lung adenocarcinoma.

Li Y, Cai Y, Ji L, Wang B, Shi D, Li X PeerJ. 2024; 12:e17746.

PMID: 39071134 PMC: 11276766. DOI: 10.7717/peerj.17746.

Clinical Outcome of Nivolumab Plus Ipilimumab in Patients with Locally Advanced Non-Small-Cell Lung Cancer with Relapse after Concurrent Chemoradiotherapy followed by Durvalumab.

Mouri A, Watanabe S, Tokito T, Nagai Y, Saida Y, Imai H Cancers (Basel). 2024; 16(7).

PMID: 38611087 PMC: 11011053. DOI: 10.3390/cancers16071409.

Analyses of quality of life in cancer drug trials - a review of measurements and analytical choices in post-reimbursement studies.

Svensson M, Chauca Strand G, Bonander C, Johansson N, Jakobsson N BMC Cancer. 2024; 24(1):311.

PMID: 38448848 PMC: 10916053. DOI: 10.1186/s12885-024-12045-8.

References

Peters S, Adjei A, Gridelli C, Reck M, Kerr K, Felip E . Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii56-64. DOI: 10.1093/annonc/mds226. View

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Freeman G, Long A, Iwai Y, Bourque K, Chernova T, Nishimura H . Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000; 192(7):1027-34. PMC: 2193311. DOI: 10.1084/jem.192.7.1027. View

Abe T, Takeda K, Ohe Y, Kudoh S, Ichinose Y, Okamoto H . Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: the intergroup trial JCOG0803/WJOG4307L. J Clin Oncol. 2015; 33(6):575-81. DOI: 10.1200/JCO.2014.55.8627. View

Gettinger S, Horn L, Gandhi L, Spigel D, Antonia S, Rizvi N . Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(18):2004-12. PMC: 4672027. DOI: 10.1200/JCO.2014.58.3708. View

Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I . Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations. Eur Respir J. 2011; 39(1):9-28. DOI: 10.1183/09031936.00190310. View

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Natale R, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F . Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II.... J Thorac Oncol. 2014; 9(11):1704-8. PMC: 4340255. DOI: 10.1097/JTO.0000000000000285. View

10.

Blumenthal G, Karuri S, Zhang H, Zhang L, Khozin S, Kazandjian D . Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015; 33(9):1008-14. PMC: 4356710. DOI: 10.1200/JCO.2014.59.0489. View

11.

Murakami H, Yamanaka T, Seto T, Sugio K, Okamoto I, Sawa T . Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. Cancer Sci. 2014; 105(8):989-95. PMC: 4317856. DOI: 10.1111/cas.12448. View

12.

Rizvi N, Mazieres J, Planchard D, Stinchcombe T, Dy G, Antonia S . Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015; 16(3):257-65. PMC: 5726228. DOI: 10.1016/S1470-2045(15)70054-9. View

13.

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A . Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001; 291(5502):319-22. DOI: 10.1126/science.291.5502.319. View

14.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

15.

Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge D . A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J Thorac Oncol. 2014; 9(7):1031-1035. DOI: 10.1097/JTO.0000000000000183. View

16.

Garassino M, Martelli O, Broggini M, Farina G, Veronese S, Rulli E . Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013; 14(10):981-8. DOI: 10.1016/S1470-2045(13)70310-3. View

17.

Li R, Sun L, Wang J, Qian J, Wang Z, Jiao X . Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients. Pulm Pharmacol Ther. 2012; 25(5):364-70. DOI: 10.1016/j.pupt.2012.06.008. View

18.

Prentice R . Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med. 1989; 8(4):431-40. DOI: 10.1002/sim.4780080407. View

19.

Tsujino K, Kawaguchi T, Kubo A, Aono N, Nakao K, Koh Y . Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol. 2009; 4(8):994-1001. DOI: 10.1097/JTO.0b013e3181a94a2f. View

20.

Hotta K, Suzuki E, Di Maio M, Chiodini P, Fujiwara Y, Takigawa N . Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer. Lung Cancer. 2012; 79(1):20-6. DOI: 10.1016/j.lungcan.2012.10.007. View